Ixekizumab — Membership Pricing

Other medications in Rheumatology

• Mycophenolate
• Probenecid
• Rilonacept
• Risankizumab
• Sarilumab
• Secukinumab
• Tocilizumab
• Tofacitinib

About Ixekizumab

Ixekizumab is a powerful biologic medication prescribed for chronic inflammatory conditions such as psoriasis and psoriatic arthritis. It offers significant relief for many patients by targeting specific pathways of inflammation. Understanding its role and managing its cost can be complex, but TheDrugClub is dedicated to simplifying access to potential savings and benefits, helping you manage your prescription expenses effectively.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ixekizumab is approved for (FDA label)

TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 ) 1.1 Plaque Psoriasis TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Non-radiographic Axial Spondyloarthritis TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

Source: Read the full FDA label on DailyMed. Label effective date: January 22, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ixekizumab (FDA label)

TALTZ is a clear and colorless to slightly yellow solution available as: Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled autoinjector Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled syringe Injection: 40 mg/0.5 mL solution of TALTZ in a single-dose prefilled syringe Injection: 20 mg/0.25 mL solution of TALTZ in a single-dose prefilled syringe Injection: ( 3 ) 80 mg/mL solution in a single-dose prefilled autoinjector 80 mg/mL solution in a single-dose prefilled syringe 40 mg/0.5 mL solution in a single-dose prefilled syringe 20 mg/0.25 mL solution in a single-dose prefilled syringe

Source: FDA prescribing information (DailyMed). Set ID: ac96658a-d7dc-4c7c-8928-2adcdf4318b2. SPL document ID: 1c6425de-1f8c-4385-bfb9-6e01db55275f. Label effective date: January 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ixekizumab (FDA label)

The following adverse drug reactions are discussed in greater detail in other sections of the label: Infections [see Warnings and Precautions ( 5.1 )] Hypersensitivity Reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.3 )] Eczematous Eruptions [see Warnings and Precautions ( 5.4 )] Inflammatory Bowel Disease [see Warnings and Precautions ( 5.5 )] Most common (≥1%) adverse reactions associated with TALTZ treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-545-5979 (1-800-LillyRx) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: ac96658a-d7dc-4c7c-8928-2adcdf4318b2. SPL document ID: 1c6425de-1f8c-4385-bfb9-6e01db55275f. Label effective date: January 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ixekizumab (FDA label)

TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients [see Warnings and Precautions ( 5.3 )] . Serious hypersensitivity reaction to ixekizumab or to any of the excipients. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: ac96658a-d7dc-4c7c-8928-2adcdf4318b2. SPL document ID: 1c6425de-1f8c-4385-bfb9-6e01db55275f. Label effective date: January 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ixekizumab (FDA label)

Infections : Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue TALTZ until the infection resolves. ( 5.1 ) Tuberculosis (TB) : Evaluate for TB prior to initiating treatment. ( 5.2 ) Hypersensitivity : If a serious allergic reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy. ( 5.3 ) Eczematous Eruptions: In the postmarketing setting, cases of severe eczematous eruptions were reported in patients receiving TALTZ. Treatment may need to be discontinued to resolve the eczematous eruption. ( 5.4 ) Inflammatory Bowel Disease : Crohn's disease and ulcerative colitis, including exacerbations, occurred during clinical trials. Monitor closely when prescribing TALTZ to patients with inflammatory bowel disease (IBD).

Source: FDA prescribing information (DailyMed). Set ID: ac96658a-d7dc-4c7c-8928-2adcdf4318b2. SPL document ID: 1c6425de-1f8c-4385-bfb9-6e01db55275f. Label effective date: January 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.